BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15648953)

  • 1. CYC-202 Cyclacel.
    Guzi T
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1311-8. PubMed ID: 15648953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MS-209 Schering.
    Robert J
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1340-7. PubMed ID: 15648956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CC-5013 (Celgene).
    Mitsiades CS; Mitsiades N
    Curr Opin Investig Drugs; 2004 Jun; 5(6):635-47. PubMed ID: 15242253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epothilone D (Kosan/Roche).
    Kolman A
    Curr Opin Investig Drugs; 2004 Jun; 5(6):657-67. PubMed ID: 15242255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BMS-247550 Bristol-Myers Squibb/GBF.
    Lin N; Brakora K; Seiden M
    Curr Opin Investig Drugs; 2003 Jun; 4(6):746-56. PubMed ID: 12901236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. AE-941 (AEterna).
    Dredge K
    Curr Opin Investig Drugs; 2004 Jun; 5(6):668-77. PubMed ID: 15242256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. OSI-461 (OSI).
    Galmarini CM
    Curr Opin Investig Drugs; 2004 Jun; 5(6):648-56. PubMed ID: 15242254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technology evaluation: cantuzumab mertansine, ImmunoGen.
    Smith SV
    Curr Opin Mol Ther; 2004 Dec; 6(6):666-74. PubMed ID: 15663331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diflomotecan. Ipsen.
    Osheroff N
    IDrugs; 2004 Mar; 7(3):257-63. PubMed ID: 15011101
    [No Abstract]   [Full Text] [Related]  

  • 10. Technology evaluation: Kahalalide F, PharmaMar.
    Hamann MT
    Curr Opin Mol Ther; 2004 Dec; 6(6):657-65. PubMed ID: 15663330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Learning from exceptional drug responders.
    Mullard A
    Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
    [No Abstract]   [Full Text] [Related]  

  • 12. Su-11248 Sugen.
    Sakamoto KM
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1329-39. PubMed ID: 15648955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BAY-43-9006 Bayer/Onyx.
    Lee JT; McCubrey JA
    Curr Opin Investig Drugs; 2003 Jun; 4(6):757-63. PubMed ID: 12901237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 27th Annual JPMorgan Healthcare Conference--BioCryst and Emergent Biosolutions.
    Croasdell G; Gale S
    IDrugs; 2009 Mar; 12(3):149-51. PubMed ID: 19333891
    [No Abstract]   [Full Text] [Related]  

  • 15. 27th Annual JPMorgan Healthcare Conference--Antisoma and Keryx Biopharmaceuticals.
    Croasdell G; Gale S
    IDrugs; 2009 Mar; 12(3):152-4. PubMed ID: 19333892
    [No Abstract]   [Full Text] [Related]  

  • 16. American society of clinical oncology - 45th annual meeting. Part 2.
    Lakeram M; Kibble A
    IDrugs; 2009 Jul; 12(7):404-8. PubMed ID: 19579155
    [No Abstract]   [Full Text] [Related]  

  • 17. American society of clinical oncology - 45th annual meeting. Part 1.
    Gale S
    IDrugs; 2009 Jul; 12(7):401-3. PubMed ID: 19579154
    [No Abstract]   [Full Text] [Related]  

  • 18. ZD-6126 AstraZeneca.
    Soltau J; Drevs J
    IDrugs; 2004 Apr; 7(4):380-7. PubMed ID: 15057644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug discovery conference 2008. Small-Molecule Drug Discovery: From Early Stage to the Clinic.
    Terrett NK
    IDrugs; 2008 Mar; 11(3):164-8. PubMed ID: 18311648
    [No Abstract]   [Full Text] [Related]  

  • 20. TG-4010 Transgene.
    Cohen S; Kaufman HL
    Curr Opin Investig Drugs; 2004 Dec; 5(12):1319-28. PubMed ID: 15648954
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.